Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cara Therapeutics Inc CARA

Healthcare Cannabis
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated... see more

Recent & Breaking News (NDAQ:CARA)

FinancialBuzz.com: The Growth of Legal Cannabis Products

PR Newswire March 13, 2017

Cara Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results

GlobeNewswire March 9, 2017

Cannabinoid (CBD) Research and Development Remains Incredibly Strong in Spite of Federal Hesitation on Recreational Marijuana use

PR Newswire Europe Non Regulatory March 6, 2017

Legal Cannabis Market Might be Beneficial to U.S. Economy

PR Newswire March 3, 2017

Cara Therapeutics to Announce Fourth Quarter and Full Year 2016 Financial Results on March 9, 2017

GlobeNewswire March 2, 2017

Technical Reports on Biotech Stocks -- Halozyme Therapeutics, CytRx, Cara Therapeutics, and Keryx Biopharma

PR Newswire March 2, 2017

FinancialBuzz.com: Legal Cannabis Market Projected to Become a Major Job Creation Force

PR Newswire February 28, 2017

Americans' Favorable Outlook on the Cannabis Market

PR Newswire February 17, 2017

Cliffs Natural Shares Are Hot Hot Hot For Shorts, And So Are These Other 5

Benzinga.com  February 14, 2017

FinancialBuzz.com: Legal Cannabis Market Gains Popularity

PR Newswire February 7, 2017

Spending on Legal Cannabis Accelerates

PR Newswire February 3, 2017

2017 Legal Cannabis Market Developments

PR Newswire January 11, 2017

Research Reports Coverage on Biotech Stocks -- Cara Therapeutics, Heat Biologics, Vanda Pharma, and Opexa Therapeutics

PR Newswire January 10, 2017

The Cannabis Market Enters 2017 on a Strong Footing

PR Newswire January 5, 2017

The Mainstream Growth of the Cannabidiol Market

PR Newswire December 23, 2016

Emerging Cannabis Market Poised to Grow

PR Newswire December 15, 2016

Legal Cannabis Market is Gaining Attention

PR Newswire December 8, 2016

Cannabis Sales to Grow Faster in Coming Years

PR Newswire December 5, 2016

Cannabis Industry Expects to Become the Next Biggest Market

PR Newswire November 30, 2016

Cara Therapeutics Completes Planned Enrollment of Eight-Week Multi-Dose Phase of Adaptive Trial of I.V. CR845 in Chronic Kidney Disease-Associated Pruritus

GlobeNewswire November 29, 2016